Rachel is Professor of Health Economics at the University of Manchester, Lead for the Manchester Centre for Health Economics (MCHE), NIHR Senior Investigator,  and Visiting Professor at the University of Queensland, Australia. She has brought in over £58 million funding in applied health economics research which has influenced health policy and practice in the UK and internationally, completed a Harkness Fellowship at Harvard Medical School and has authored two books and over 150 research publications. Research themes include medicines safety and adherence, digital health technology, diabetes, antibiotics, mental health and dementia. She has experience of working closely with the National Health Service in the UK and patient stakeholders in the development and evaluation of a pharmacist/IT complex intervention in primary care, PINCER (RCT, regional and national roll-out), the Electronic Prescription Service, the New Medicine Service, new NHS medicines interoperability information standards and Pharmacy First. A key research area has been the economic impact of medication error, with specific interest in understanding both health and non-health outcomes associated with cross-therapeutic interventions. She is currently the economics lead for the NIHR Patient Safety Research Collaboration based in Manchester. She has recently finished her term as Director of Manchester Clinical Trials Unit. She is chair of the Selection Panel for the NIHR Advanced Clinical and Practitioner Academic Fellowship Awards. She is on the editorial board for Pharmacoeconomics, associate editor for International Journal of Pharmacy Practice, has completed two terms as chair of the Pharmacy Research UK (PRUK) Scientific Advisory Panel and is now is a PRUK trustee. She was a member of a NICE technology appraisal committee from 2006-23, involved in the Cancer Drugs Fund review (2016) and was lead economist on the specially convened COVID technology NICE appraisals panel (2022). She is a regular contributor to international advisory boards around pharmaceutical, biological and advanced therapy HTA and reimbursement. She is a UK registered pharmacist, the first full-time critical care pharmacist in the UK and completed a DH funded Phd in health economics (1996). She is committed to supporting research career development. She has set up internships and provided pre-registration training to support graduates to develop skills in research, and many of those individuals have stayed on in her group to complete Phds. She has supervised multiple MSc students and 19 PhD students to graduation, from a range of professional backgrounds and from a range of countries. She is a member of the Belgian Fonds voor Wetenschappelijk Onderzoek – Vlaanderen review panel for doctorate fellowships. She contributes to Athena Swan and women in leadership activities, advocacy for groups under-represented in the research community, running action learning sets, and providing mentoring and career workshops for early and mid-career researchers and academics. She is an active mentor for NIHR and the Society of Social Medicine. She works closely with patients and service users in all aspects of her work, to expand their role in health economics research codesign and dissemination.